Amedisys (AMED) Competitors

Amedisys (NASDAQ:AMED) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking.

Do analysts prefer AMED or CHE?

Amedisys currently has a consensus target price of $100.67, indicating a potential upside of 9.53%. Chemed has a consensus target price of $641.50, indicating a potential upside of 15.58%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Chemed	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor AMED or CHE?

Amedisys received 163 more outperform votes than Chemed when rated by MarketBeat users. However, 63.48% of users gave Chemed an outperform vote while only 58.72% of users gave Amedisys an outperform vote.

Company	Underperform	Outperform
Amedisys	Outperform Votes 495 58.72%	Underperform Votes 348 41.28%
Chemed	Outperform Votes 332 63.48%	Underperform Votes 191 36.52%

Do institutionals & insiders hold more shares of AMED or CHE?

94.4% of Amedisys shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 2.1% of Amedisys shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more volatility & risk, AMED or CHE?

Amedisys has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.

Which has higher valuation & earnings, AMED or CHE?

Chemed has lower revenue, but higher earnings than Amedisys. Chemed is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amedisys	$2.32B	1.30	-$9.75M	$2.52	36.47
Chemed	$2.26B	3.69	$272.51M	$19.79	28.04

Does the media prefer AMED or CHE?

In the previous week, Chemed had 1 more articles in the media than Amedisys. MarketBeat recorded 3 mentions for Chemed and 2 mentions for Amedisys. Chemed's average media sentiment score of 1.73 beat Amedisys' score of 0.75 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amedisys	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is AMED or CHE more profitable?

Chemed has a net margin of 12.69% compared to Amedisys' net margin of 3.57%. Chemed's return on equity of 27.86% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amedisys	3.57%	12.20%	6.74%
Chemed	12.69%	27.86%	19.12%

Summary

Chemed beats Amedisys on 14 of the 18 factors compared between the two stocks.